Problem

Starling addresses a large, underserved urinary-health problem, especially recurrent urinary tract infections (rUTIs), which are typically managed reactively through symptoms, office visits, urine samples, and antibiotics. The resulting burden falls on both patients and clinicians: patients may face recurring infections and difficult access to care, while providers lack continuous data to identify deterioration early. Starling frames the economics as substantial, citing an estimated 150 million UTIs worldwide each year and $6 billion in annual healthcare costs, alongside the potential to reduce avoidable hospitalizations and unnecessary clinical workload.

The main use case is preventive management of patients with recurrent UTIs. Daily urinary trends can help detect possible changes before symptoms become severe, enable earlier intervention, support better antibiotic stewardship, and reduce routine exchanges that consume urology and primary-care capacity. The model may be particularly valuable for elderly or rural patients who have difficulty accessing traditional care settings.

Product / Service

Starling’s core product, UrinDx, is an at-home urine-monitoring device designed to become part of a normal bathroom routine. A toilet-integrated spectrophotometer analyzes urine during use and generates a personalized profile of urinary trends. The device connects to Starling’s smartphone app, while the company’s algorithms and care team review incoming information; UrinDx sends data nightly, and the team contacts the patient when a clinically concerning change warrants follow-up.

The service is delivered through healthcare providers rather than as a stand-alone hardware sale. Eligible rUTI patients receive the device through partner clinics, with insurance potentially covering the program and Starling providing the device at no charge. Starling’s nurses monitor the data, provide coaching and triage, coordinate with clinicians, and help practices obtain reimbursement; the company invoices practices at a flat monthly rate. Starling is also developing Pete, a no-prescription consumer product planned to ship in 2026 for hydration and urine-clarity tracking, separate from the prescription-oriented UrinDx program.

Market

Starling competes in digital health medical devices, home urinalysis, predictive urinary diagnostics, and remote patient monitoring. Its differentiated approach is continuous or routine bathroom-based monitoring rather than episodic testing with sample cups or dipsticks. Adjacent competitors and substitutes include Healthy.io’s smartphone-enabled home urinalysis platform and other home urine-testing companies such as Scanwell Health, TestCard, Mira, and inui Health, as well as conventional dipsticks and laboratory or clinic-based urinalysis.

The company appears to be at an early commercial stage rather than purely pre-revenue, but not yet a scaled business. Starling is a YC Winter 2022 and AARP-backed startup; reported milestones include Stanford validation of predictive models, a $3.4 million seed round, a 40-patient, 12-month pilot with reimbursement from Aetna, BCBS, and Medicare, and a Wellstar investment with a pilot in development. A founder-confirmed 2026 profile describes a contract with a large urology-care partner and a planned commercial launch to 2,000 patients, targeting $1.5 million in ARR and four large urology sites, with contracts that could exceed $20 million in ARR at scale. Those figures indicate meaningful pipeline and commercialization activity, but the available evidence does not establish that the projected revenue or scale has already been realized.